Drug intelligence / Profile preview

NEST-2

Development stage: Unknown
Lead developer: Nested Therapeutics
Modality: Small Molecules

Overview

**NEST-2** is a **transcription factors stimulant** developed by **Nested Therapeutics, Inc.** for potential use in oncology. It aims to modulate transcription factor activity to influence gene expression, though specific indications and detailed mechanisms remain limited in public data. The program has reached a global highest R&D status of **Discontinued**, indicating termination of further development.[1]

Targets

TF (Transferrin)

Beyond the preview

Go deeper on NEST-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEST-2.

Explore the full profile